ADVENT CAPITAL MANAGEMENT /DE/ - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 32 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
ADVENT CAPITAL MANAGEMENT /DE/ ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2020$12,963,000
+7.5%
18,604,000
+11.4%
0.29%
+1.1%
Q2 2020$12,060,000
-16.5%
16,703,000
+0.7%
0.28%
-9.9%
Q1 2020$14,449,000
+335.6%
16,582,000
+563.3%
0.31%
+390.6%
Q4 2019$3,317,0002,500,0000.06%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q4 2019
NameSharesValueWeighting ↓
Context Capital Management, LLC 2,500,000$2,486,0001.44%
HIGHBRIDGE CAPITAL MANAGEMENT LLC 20,000,000$19,894,0001.32%
SSI INVESTMENT MANAGEMENT LLC 6,154,000$6,089,0000.45%
CSS LLC/IL 7,750,000$7,713,0000.44%
Senvest Management, LLC 5,000,000$4,998,0000.44%
Antara Capital LP 2,000,000$1,989,0000.43%
LINDEN ADVISORS LP 28,527,000$28,380,0000.43%
Graham Capital Management, L.P. 10,650,000$10,579,0000.31%
WOLVERINE ASSET MANAGEMENT LLC 19,000,000$18,904,0000.25%
Polar Asset Management Partners Inc. 10,000,000$9,957,0000.18%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders